---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-105590"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:43:26.394034+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025

## Summary
- Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.
- CT-P72/ABP-102 shows potent anti-tumor activity in HER2-high models including Enhertu-resistant tumors.
- Dual-affinity engineering reduces off-tumor activation; favorable safety in monkeys up to 90 mg/kg.
- Data supports advancement toward first-in-human trial planned for next year.

## SEC filing metadata
- accession: 0001213900-25-105590
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025105590/0001213900-25-105590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025105590/ea0263790-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-105590
- JSON: https://secwatch.observer/filing/0001213900-25-105590.json
- Plain text: https://secwatch.observer/filing/0001213900-25-105590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.